Anti-CTLA-4/PD-1 expressing EGFR-CAR-T

N/A

Report date: 2021/12/14 16:37:33

Base Information

Drug NameAnti-CTLA-4/PD-1 expressing EGFR-CAR-T
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProgrammed cell death protein 1 modulatorsCytotoxic T-Lymphocyte-Associated Antigen 4 modulatorsT lymphocyte replacements +[4] 
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Cell Therapy Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Research Institute
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A